Generic maker urges review of $235m skinny label decision

08-09-2022

Muireann Bolger

Generic maker urges review of $235m skinny label decision

JHVEphoto / Shutterstock.com

A split Federal Circuit revived a 2017 jury verdict that Teva had infringed GSK drug | Israeli pharma firm warns of threat to availability of low-cost generic medicines.


Skinny labels, Federal Circuit, Teva, GSK, generic drug manufacturers, Teva Pharmaceuticals, Coreg, Hatch-Waxman Act, infringement, FDA

LSIPR